Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-034532
Filing Date
2026-02-03
Accepted
2026-02-03 08:58:40
Documents
143
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K d93612d10k.htm   iXBRL 10-K 4073621
2 EX-10.23 d93612dex1023.htm EX-10.23 146967
3 EX-21 d93612dex21.htm EX-21 7121
4 EX-23 d93612dex23.htm EX-23 2333
5 EX-31.1 d93612dex311.htm EX-31.1 10551
6 EX-31.2 d93612dex312.htm EX-31.2 10520
7 EX-32 d93612dex32.htm EX-32 4783
9 GRAPHIC g93612g51k51.jpg GRAPHIC 81954
  Complete submission text file 0001193125-26-034532.txt   21116395

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA teva-20251231.xsd EX-101.SCH 3237817
146 EXTRACTED XBRL INSTANCE DOCUMENT d93612d10k_htm.xml XML 4426196
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-16174 | Film No.: 26590285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)